Xiao Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiao Zhong has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Xiang Song
Department of Cardiovascular Medicine, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China
3 shared publications Ziguang Song
Department of Cardiology, The Fourth Hospital of Harbin Medical University, Harbin, 150000, China
2 shared publications- Anurag Gupta
Laboratory for Prenatal Medicine, University Women's Hospital/Department of Research, University Hospital, Basel, Switzerland
1 shared publication - Bernhard Zimmermann
RND, Natera, San Carlos, CA, USA
1 shared publication Guangping Chen
Department of Physiology, Emory University School of Medicine, Atlanta, Georgia
1 shared publicationMingyang Li
Department of Cardiology, The Fourth Hospital of Harbin Medical University, Harbin, 150000, China
1 shared publication
Latest Publications
- Open Access
- 18 August 2022
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2022, 1-13
Identification of an Epigenetic Signature for Coronary Heart Disease in Postmenopausal Women's PBMC DNA
Menopause is accompanied with an increased risk of cardiovascular disease. DNA methylation may have a significant impact on postmenopausal women's development of coronary heart disease. DNA methylation alterations in peripheral blood mononuclear cells (PBMCs) from women with coronary heart disease and healthy controls were detected using the Illumina Infinium MethylationEPIC BeadChip platform in this work. We employed Sangerbox technology and the GO and KEGG databases to further study the pathogenesis of coronary heart disease in postmenopausal women. After that, we used functional epigenetic module analysis and Cytoscape to remove the hub genes from the protein-protein interaction networks. Five genes (FOXA2, PTRD, CREB1, CTNAP2, and FBN2) were the hub genes. Lipid accumulation, endothelial cell failure, inflammatory responses, monocyte recruitment and aggregation, and other critical biological processes were all influenced by these genes. Finally, we employed methylation-specific PCR to demonstrate that FOXA2 was methylated at a high level in postmenopausal women with coronary heart disease. To better understand coronary heart disease in postmenopausal women's molecular mechanisms, our study examine the major factors contributing to the state of DNA methylation modification, which will help discover novel diagnostic tools and treatment options.
- 18 August 2022
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2022, 1-13
Open AccessIdentification of an Epigenetic Signature for Coronary Heart Disease in Postmenopausal Women's PBMC DNA
Menopause is accompanied with an increased risk of cardiovascular disease. DNA methylation may have a significant impact on postmenopausal women's development of coronary heart disease. DNA methylation alterations in peripheral blood mononuclear cells (PBMCs) from women with coronary heart disease and healthy controls were detected using the Illumina Infinium MethylationEPIC BeadChip platform in this work. We employed Sangerbox technology and the GO and KEGG databases to further study the pathogenesis of coronary heart disease in postmenopausal women. After that, we used functional epigenetic module analysis and Cytoscape to remove the hub genes from the protein-protein interaction networks. Five genes (FOXA2, PTRD, CREB1, CTNAP2, and FBN2) were the hub genes. Lipid accumulation, endothelial cell failure, inflammatory responses, monocyte recruitment and aggregation, and other critical biological processes were all influenced by these genes. Finally, we employed methylation-specific PCR to demonstrate that FOXA2 was methylated at a high level in postmenopausal women with coronary heart disease. To better understand coronary heart disease in postmenopausal women's molecular mechanisms, our study examine the major factors contributing to the state of DNA methylation modification, which will help discover novel diagnostic tools and treatment options.
- 30 June 2020
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 47 (11) , 1808-1815
Survival motor neuron protein protects H9c2 cardiomyocytes from hypoxia‐induced cell injury by reducing apoptosis
Background: Hypoxia induces cell injury in cardiomyocytes and leads to the development of cardiovascular diseases. The survival motor neuron protein (SMN) is a crucial ubiquitous protein whose functional deficiency causes motor neuron loss seen in spinal muscular atrophy. SMN has shown protective effects on the cardiovascular system and the aim of the present study was to investigate the cardioprotective effects of SMN on hypoxia‐induced cell injury.Methods: Cobalt chloride (CoCl2) was used to induce chemical hypoxia in H9c2 cardiomyocytes. Cell proliferation was determined by the MTT assay and the mRNA levels of SMN were evaluated by real‐time polymerase chain reaction. The protein expression levels of SMN, hypoxia‐inducible transcription factor 1α (HIF‐1α), and apoptosis‐related proteins, such as cytochrome c (Cyt c), B cell lymphoma‐2 (Bcl‐2), Bcl‐2 associated X protein (Bax), and cleaved caspase‐3 were evaluated by western blot analysis. Cell apoptosis was analysed using annexin V/propidium iodide (PI) staining.Results: Treatment with CoCl2 significantly reduced H9c2 cell viability; the level of HIF‐1α, which is a hypoxia‐related indicator increased whereas the expression of SMN protein decreased. Hypoxia also induced cardiomyocyte apoptosis, indicated by reduced Bcl‐2 expression and elevated cleaved caspase‐3, Bax, and cytochrome c levels. Interestingly, SMN, which is a neuron protection factor, ameliorated CoCl2‐induced cell damage by reducing cardiomyocyte apoptosis through upregulation of Bcl‐2 and inhibition of cytochrome c, cleaved caspase‐3, and Bax expression.Conclusion: Survival motor neuron prevents hypoxia‐induced cell apoptosis through inhibition of the mitochondrial apoptotic pathway, and thereby exerts a protective effect on H9c2 cardiomyocytes.
- 30 June 2020
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 47 (11) , 1808-1815
Survival motor neuron protein protects H9c2 cardiomyocytes from hypoxia‐induced cell injury by reducing apoptosis
Background: Hypoxia induces cell injury in cardiomyocytes and leads to the development of cardiovascular diseases. The survival motor neuron protein (SMN) is a crucial ubiquitous protein whose functional deficiency causes motor neuron loss seen in spinal muscular atrophy. SMN has shown protective effects on the cardiovascular system and the aim of the present study was to investigate the cardioprotective effects of SMN on hypoxia‐induced cell injury.Methods: Cobalt chloride (CoCl2) was used to induce chemical hypoxia in H9c2 cardiomyocytes. Cell proliferation was determined by the MTT assay and the mRNA levels of SMN were evaluated by real‐time polymerase chain reaction. The protein expression levels of SMN, hypoxia‐inducible transcription factor 1α (HIF‐1α), and apoptosis‐related proteins, such as cytochrome c (Cyt c), B cell lymphoma‐2 (Bcl‐2), Bcl‐2 associated X protein (Bax), and cleaved caspase‐3 were evaluated by western blot analysis. Cell apoptosis was analysed using annexin V/propidium iodide (PI) staining.Results: Treatment with CoCl2 significantly reduced H9c2 cell viability; the level of HIF‐1α, which is a hypoxia‐related indicator increased whereas the expression of SMN protein decreased. Hypoxia also induced cardiomyocyte apoptosis, indicated by reduced Bcl‐2 expression and elevated cleaved caspase‐3, Bax, and cytochrome c levels. Interestingly, SMN, which is a neuron protection factor, ameliorated CoCl2‐induced cell damage by reducing cardiomyocyte apoptosis through upregulation of Bcl‐2 and inhibition of cytochrome c, cleaved caspase‐3, and Bax expression.Conclusion: Survival motor neuron prevents hypoxia‐induced cell apoptosis through inhibition of the mitochondrial apoptotic pathway, and thereby exerts a protective effect on H9c2 cardiomyocytes.
- Open Access
- 29 October 2018
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 46 (3) , 197-203
The role of galectin‐3 in heart failure and cardiovascular disease
Summary: Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin‐3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
- 29 October 2018
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 46 (3) , 197-203
Open AccessThe role of galectin‐3 in heart failure and cardiovascular disease
Summary: Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin‐3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
- Open Access
- 9 August 2003
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 133 (3132) , 442-445
Determination of RHD zygosity using real-time quantitative PCR
At present RHD incompatibility is still an obstetric problem despite prophylactic treatment. A very welcome recent technical advance has now made it possible to determine the foetal RHD status in a non-invasive risk-free manner using cell free foetal DNA in maternal plasma. In some cases, however, where there is a high risk that the foetus may be affected by HDN (haemolytic disease of the newborn), it may be of interest to determine whether the father is hetero- or homozygous for the RHD gene, since in the former instance there is only a 50% chance that the pregnancy is affected. It has recently been shown that quantitative PCR assays, in particular real-time Taqman PCR, can be used to determine the RHD gene dosage, and also to determine foetal aneuploidies. We demonstrate that the same real-time Taqman PCR assay we had previously developed for non-invasive analysis of the foetal RHD gene and the foetal Y chromosome from maternal plasma can be used to determine the paternal RHD genotype.
- 9 August 2003
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 133 (3132) , 442-445
Open AccessDetermination of RHD zygosity using real-time quantitative PCR
At present RHD incompatibility is still an obstetric problem despite prophylactic treatment. A very welcome recent technical advance has now made it possible to determine the foetal RHD status in a non-invasive risk-free manner using cell free foetal DNA in maternal plasma. In some cases, however, where there is a high risk that the foetus may be affected by HDN (haemolytic disease of the newborn), it may be of interest to determine whether the father is hetero- or homozygous for the RHD gene, since in the former instance there is only a 50% chance that the pregnancy is affected. It has recently been shown that quantitative PCR assays, in particular real-time Taqman PCR, can be used to determine the RHD gene dosage, and also to determine foetal aneuploidies. We demonstrate that the same real-time Taqman PCR assay we had previously developed for non-invasive analysis of the foetal RHD gene and the foetal Y chromosome from maternal plasma can be used to determine the paternal RHD genotype.